Updated Recommendations for the Diagnosis and Management of Osteoporosis: A Local Perspective
Tóm tắt
Từ khóa
Tài liệu tham khảo
Cooper C, 1992, Hip fractures in the elderly: A worldwide projection, Osteoporos Int, 2, 285, 10.1007/BF01623184
NIH consensus development panel on osteoporosis prevention diagnosis and therapy. South Med J . 2001; 94 :569-73.
Brown JP, 2002, Scientific advisory council of the osteoporosis society of Canada.2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada, CMAJ, 167, S1
Tzaphlidou M, 2008, Bone architechture: Collagen structure and calcium/phosphorus maps, J Biol Phys, 34, 39, 10.1007/s10867-008-9115-y
Crabtree NJ, 2002, Improving risk assessment: Hip geometry, bone mineral distribution and bone strength in hip fracture cases and controls.The Epos study, Osteoporosis Int, 13, 48, 10.1007/s198-002-8337-y
Crans GG, 2004, Association of severe vertebral fractures with reduced quality of life, Arthritis Rheum, 50, 4028, 10.1002/art.20671
Hasserius R, 2003, European Vertebral Osteoporosis Study. Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: A 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study, Osteoporosis Int, 14, 61, 10.1007/s00198-002-1316-9
Braithwaite RS, 2003, Estimating hip fracture morbidity, mortality, and costs, J Am Geriatr Soc, 51, 364, 10.1046/j.1532-5415.2003.51110.x
El-Desouki MI, 1999, Osteoporosis in postmenopausal Saudi women using dual X-ray bone densitometry, Saudi Med J, 20, 283
Ghannam NN, 1999, Bone mineral density of the spine and femur in healthy Saudi females: Relation to vitamin D status, pregnancy, and lactation, Calci Tissue Int, 65, 23, 10.1007/s002239900652
Dougherty G, 2001, Bone density measured by dual-energy X absorptiometry in healthy Kuwaity women, Calcif Tissue Int, 68, 225, 10.1007/s002230020015
Ardawi MS, 2005, Bone mineral density of the spine and femur in healthy Saudi Arabs, Osteoporos Int, 16, 43, 10.1007/s00198-004-1639-9
Baddoura R, 2001, Incidence of fractures after the age of 50 years in the Lebanese population and implications in terms of osteoporosis, Rev Epidemiol Sante Publique, 49, 27
Al-Nuaim AR, 1999, Incidence of proximal femur fracture in an urbanized community in Saudi Arabia, Calcif Tissue Int, 56, 536, 10.1007/BF00298585
Gannagé-Yared MH, 2000, Hypovitaminosis D in a Sunny Country: Relation to Lifestyle and Bone Markers, J Bone Miner Res, 15, 1856, 10.1359/jbmr.2000.15.9.1856
El-Hajj Fuleihan G, 2001, Hypovitaminosis D in schoolchildren, Pediatrics, 107, E53, 10.1542/peds.107.4.e53
Fonseca V, 1984, Exposure to sunlight and vitamin D deficiency in Saudi Arabian women, Postgrad Med J, 60, 589, 10.1136/pgmj.60.707.589
Taha SA, 1984, 25-Hydroxyvitamin D and total calcium: Extraordinarily low plasma concentrations in Saudi mothers and their neonates, Pediatr Res, 18, 739, 10.1203/00006450-198408000-00013
Salamoun MM, 2005, Low calcium and vitamin D intake in healthy children and adolescents and their correlates, Eur j Clin nutri, 59, 177, 10.1038/sj.ejcn.1602056
Gannagé-Yared MH, 2005, Dietary calcium and vitamin D intake in an adult Middle Eastern population: Food sources and relation to lifestyle and PTH, Int J Vitam Nutr Res, 75, 281, 10.1024/0300-9831.75.4.281
Awumey EM, 1998, Vitamin D metabolism is altered in Asians Indians in the southern united states, J Clin Endocrinol Metab, 83, 169
Lips P, 2001, A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: Baseline data from the multiple outcomes of raloxifene evaluation clinical trial, J Clin Endocrinol Metab, 86, 1212, 10.1210/jcem.86.3.7327
Raef H, 2004, The effect of vitamin D status on the severity of bone disease and on the other features of primary hyperparathyroidism (pHPT) in a vitamin D deficient region, J Endocrinol Invest, 27, 807, 10.1007/BF03346273
Nelson HD, 2002, Screening for postmenopausal osteoporosis: A review of the evidence for the US. Preventive Service Task Force, Ann Intern Med, 137, 529, 10.7326/0003-4819-137-6-200209170-00015
Wilkin TJ, 1999, Changing perceptions in osteoporosis, BMJ, 318, 862
Black DM, 2011, An Assessment Tool for Predicting Risk in Postmenopausal Women, Osteoporos Int, 12, 519, 10.1007/s001980170072
Kanis JA . on behalf of the World Health Organisation Scientific Group. 2007 WHO publication. Assessment of osteoporosis at the primary health care level WHO Collaborating Centre for Metabolic Bone Diseases University of Sheffield (Available on request from the WHO Collaborating Centre or the IOF).
Tosteson AN, 2008, Cost-effective osteoporosis treatment thresholds: The United States perspective, Osteoporos Int, 19, 437, 10.1007/s00198-007-0550-6
Akkus Z, 2005, Determination of osteoporosis risk factors using a multiple logistic regression model in postmenopausal Turkish women, Saudi Med J, 26, 1351
Maalouf G, 2007, Middle East and North Africa consensus on osteoporosis, J Musculoskelet Neuronal Interact, 7, 131
Baddoura R, 2007, Vertebral fracture risk and impact of database selection on identifying elderly Lebanese with osteoporosis, Bone, 40, 1066, 10.1016/j.bone.2006.11.016
U.S. Preventive Services Task Force Screening for osteoporosis in postmenopausal women: Recommendations and rationale. Ann Intern Med . 2002; 137 :526-8.
Clinicians guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation Last accessed on 2008 Available from: http://www.nof.org .
Siris ES, 2001, Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: Results from the national osteoporosis risk assessment, JAMA, 286, 2815, 10.1001/jama.286.22.2815
Sornay-Rendu E, 2005, Indentification of Osteopenic Women at high risk of frature: The OFELY study, J Bone Miner Res, 20, 1813, 10.1359/JBMR.050609
Khan AA, 2006, Premenopausal women and low bone density, Can Fam Physcian, 52, 743
Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum . 2001; 44 :1496-503 American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.
Eastell R, 1998, A UK Consensus Group on management of glucocorticoid-induced osteoporosis: An update, J Intern Med, 244, 271, 10.1046/j.1365-2796.1998.00408.x
Devogelaer JP, 2006, Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: A consensus document of the Belgian Bone Club, Osteoporos Int, 17, 8, 10.1007/s00198-005-2032-z
Saag KG, 2007, Teriparatide or Alendronate in glucocorticoid-induce osteoporosis, NEJM, 357, 2028, 10.1056/NEJMoa071408
Reid M, 2009, for the HORIZON investigators Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial, Lancet, 373, 1253, 10.1016/S0140-6736(09)60250-6
Cohen A, 2003, Osteoporosis after solid organ and bone marrow transplantation, Osteoporos Int, 14, 617, 10.1007/s00198-003-1426-z
Rodino MA, 1998, Osteoporosis after organ transplantation, American Journal of Medicine, 104, 459, 10.1016/S0002-9343(98)00081-3
Lyu DM, 2009, Medical complications of lung transplantation, Proc Am Thorac Soc, 6, 101, 10.1513/pats.200808-077GO
Cohen A, 2004, Management of bone loss after organ transplantation, J Bone Miner Res, 19, 1919, 10.1359/jbmr.040912
Sambrook P, 2000, Effect of calcitriol on bone loss after cardiac or lung transplantation, J Bone and Mineral Res, 15, 1818, 10.1359/jbmr.2000.15.9.1818
De Sevaux RG, 2002, Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study, J Am Soc Nephrol, 13, 1608, 10.1097/01.ASN.0000016082.70875.36
Leidig-Bruckner G, 2001, Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: A follow-up study, Lancet, 357, 342, 10.1016/S0140-6736(00)03641-2
Cahill BC, 2001, Prevention of bone loss and fracture after lung transplantation: A pilot study, Transplantation, 72, 1251, 10.1097/00007890-200110150-00012
Coco M, 2003, Prevention of bone loss in renal transplant recipients: A prospective, randomized trial of intravenous pamidronate, J Am Soc Nephrol, 14, 2669, 10.1097/01.ASN.0000087092.53894.80
Kovac D, 2001, Prevention of bone loss in kidney graft recipients, Transplant Proc, 33, 1144, 10.1016/S0041-1345(00)02464-7
Haas M, 2003, Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation, Kidney Int, 63, 1130, 10.1046/j.1523-1755.2003.00816.x
Valero MA, 1995, Calcitonin and bisphosphonates treatment in bone loss after liver transplantation, Calcif Tissue Int, 57, 15, 10.1007/BF00298990
Grotz WH, 1998, Treatment of osteopenia and osteoporosis after kidney transplantation, Transplantation, 66, 1004, 10.1097/00007890-199810270-00007
Cejka D, 2008, Effect of teriparatide onearly bone loss after kidney transplantation, Am J Transplant, 8, 1864, 10.1111/j.1600-6143.2008.02327.x
Fleischer J, 2008, Serum testosterone levels after cardiac transplantation, Transplantation, 85, 834, 10.1097/TP.0b013e318166ac10
Aris RM, 1996, Severe osteoporosis before and after lung transplantation, Chest, 109, 1176, 10.1378/chest.109.5.1176
Desso V, 1998, Bone mass in patients with type 1 diabetes mellitus awaiting simultaneous pancreas kidney transplant, Bone, 23, 588
Conley E, 2008, Bisphosphonates and bone fractures in long-term kidney transplant recipients, Transplantation, 08, 231, 10.1097/TP.0b013e318176b40f
Spira A, 2000, Osteoporosis and lung transplantation: a prospective study, Chest, 117, 476, 10.1378/chest.117.2.476
Cohen A, 2006, Discontinuing antiresorptive therapy one year after cardiac transplantation: effect on bone density and bone turnover, Transplantation, 81, 686, 10.1097/01.tp.0000177645.63999.ca
Bianchi ML, 2007, Osteoporosis in children and adolescents, Bone, 41, 486, 10.1016/j.bone.2007.07.008
Bone density evaluation in teens prevents future osteoporosis. Arch Pediatr Adolesc Med . 2006; 160 :1026-32.
Bianchi ML, 2005, How to manage osteoporosis in children, Best Pract Res Clin Rheumatol, 19, 991, 10.1016/j.berh.2005.06.006
Bachrach LK, 2009, Clinical review 1: Bisphosphonate use in childhood osteoporosis, J Clin Endocrinol Metab, 94, 400, 10.1210/jc.2008-1531
Cromer B, 2000, Adolescents: At Increased Risk for Osteoporosis?, Clin Pediatr, 39, 565, 10.1177/000992280003901001
Vetter U, 1992, Osteogenesis imperfecta: A clinical study of the first 10 years of life, Calcif Tissue Int, 50, 36, 10.1007/BF00297295
Kauffman RP, 2001, Osteoporosis in children and adolescent girls: case report of idiopathic juvenile osteoporosis and review of the literature, Obstet Gynecol Surv, 56, 492, 10.1097/00006254-200108000-00023
Bianchi ML, 2000, Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: A prospective multicenter study, Arthritis Rheum, 43, 1960, 10.1002/1529-0131(200009)43:9<1960::AID-ANR6>3.0.CO;2-J
Shaw NJ, 2005, Bisphosphonate treatment of bone disease, Arch Dis Child, 90, 494, 10.1136/adc.2003.036590
Saadi H, 2005, Osteoporosis in Renal Failure: How accurate is the diagnosis and is there any role for bisphosphonates?, Int J Diabetes Metab, 13, 99, 10.1159/000497579
Miller PD, 2009, Diagnosis and Treatment of Osteoporosis in Chronic Renal Failure, Semin Nephrol, 29, 144, 10.1016/j.semnephrol.2009.01.007
Moe S, 2006, Definition, Evaluation and Classification of Renal Osteodystrophy: A Position Statement from Kidney Disease: Improving Global Outcomes (KDIGO), Kidney Int, 69, 1945, 10.1038/sj.ki.5000414
Miller PD, 2005, Safety and Efficacy of Risdronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: A pooled analysis of nine clinical trials, J Bone Mineral Res, 20, 2015, 10.1359/JBMR.050817
Jamal SA, 2007, Alendronate treatment in women with normal to severely impaired renal function: An analysis for the fracture intervention trial, J Bone Mineral Res, 22, 503, 10.1359/jbmr.070112
Ishani A, 2008, MORE investigators.The effect of Raloxifene treatment in post-menopausal women with CKD, J Am Sco Nehprol, 19, 1430
Miller PD, 2005, Diagnosis and Treatment of Osteoporosis or fragility fractures in patients with Chronic Kidney Disease.Osteoporosis: Clinical Update- National Osteoporosis Foundation, Summer
MacLean C, 2008, Systematic review: Comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis, Ann Intern Med, 148, 197, 10.7326/0003-4819-148-3-200802050-00198
Kanis JA, 2008, European guidance for the diagnosis and management of osteoporosis in postmenopausal women, Osteoporos Int, 19, 399, 10.1007/s00198-008-0560-z
Cranney A, 2002, Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis, Endocr Rev, 23, 570, 10.1210/er.2001-9002
Boonen S, 2005, Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies, Osteoporos Int, 16, 1291, 10.1007/s00198-005-1945-x
Ettinger B, 1999, Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial: Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators, JAMA, 282, 637, 10.1001/jama.282.7.637
Delmas PD, 2003, Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: Results from the MORE trial, Bone, 33, 522, 10.1016/S8756-3282(03)00241-2
Vogel VG, 2006, Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial, JAMA, 295, 2727, 10.1001/jama.295.23.joc60074
Barrett-Connor E, 2006, Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women, N Engl J Med, 355, 125, 10.1056/NEJMoa062462
Black DM, 1996, Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group, Lancet, 348, 1535, 10.1016/S0140-6736(96)07088-2
Cummings SR, 1998, Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial, JAMA, 280, 2077, 10.1001/jama.280.24.2077
Harris ST, 1999, Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial: Vertebral Efficacy with Risedronate Therapy (VERT) Study Group, JAMA, 282, 1344, 10.1001/jama.282.14.1344
McClung MR, 2001, Effect of risedronate on the risk of hip fracture in elderly women: Hip Intervention Program Study Group, N Engl J Med, 344, 333, 10.1056/NEJM200102013440503
Chesnut IC, 2004, Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis, J Bone Miner Res, 19, 1241, 10.1359/JBMR.040325
Delmas PD, 2004, Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: Results from the BONE study, Osteoporos Int, 15, 792, 10.1007/s00198-004-1602-9
Reginster JY, 2006, Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study, Ann Rheum Dis, 65, 654, 10.1136/ard.2005.044958
Delmas PD, 2006, Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study, Arthritis Rheum, 54, 1838, 10.1002/art.21918
Black DM, 2007, Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis, N Engl J Med, 356, 1809, 10.1056/NEJMoa067312
Lyles KW, 2007, The HORIZON Recurrent Fracture Trial: Zoledronic acid and clinical fractures and mortality after hip fracture, N Engl J Med, 357, 1799, 10.1056/NEJMoa074941
Neer RM, 2001, Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis, N Engl J Med, 344, 1434, 10.1056/NEJM200105103441904
Ahrader SP, 2005, Parathyroid hormone (1-84) and treatment of osteoporosis, Ann Pharmacother, 39, 1511, 10.1345/aph.1G146
Meunier PJ, 2004, The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis, N Engl J Med, 350, 459, 10.1056/NEJMoa022436
Reginster JY, 2008, Effects of long term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis, results of five year, randomizes, placebo-controlled trial, Arthritis and Rheumatism, 58, 1687, 10.1002/art.23461
Reginster JY, 2005, Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study, J Clin Endocrinol Metab, 90, 2816, 10.1210/jc.2004-1774
Rabenda V, 2005, Is there any interest in combining treatments in osteoporosis?, Curr Rheumatol Rev, 1, 49, 10.2174/1573397052954163
Black DM, 2003, The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis, New Engl J Med, 249, 1207, 10.1056/NEJMoa031975
Black DM, 2005, One year alendronate after one year of parathyroid hormone (1-84) for osteoporosis, N Engl J Med, 353, 555, 10.1056/NEJMoa050336
Writing Group for the Women's Health Initiative Investigators. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women. JAMA . 2002; 288 :321-33.
Writing Group for the Heart and Estrogen/ progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post menopausal women. JAMA . 1998; 280 :605-18.
Reid IR, 1993, Effect of Calcium Supplementation on Bone Loss in Postmenopausal Women, N Engl J Med, 328, 460, 10.1056/NEJM199302183280702
Gillepsie WJ, 2001, Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis, Cochrane Database Syst Rev, 1, CD000227
Chestnut CH, 2000, A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The PROOF study, Am J Med, 109, 267, 10.1016/S0002-9343(00)00490-3
Clarke B, 2008, New and Emerging Treatment for osteoporosis, Mayo Clinic Endocrinology Update, 3, 2